Veru (VERU) Non-Current Assets (2010 - 2026)
Veru (VERU) posted quarterly Non-Current Assets of $9.7 million for Q1 2026, down 13.87% year-over-year from $11.3 million in Q1 2025, and down 9.6% quarter-over-quarter from $10.8 million in Q4 2025.
Veru (VERU) Non-Current Assets (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Non-Current Assets for 17 consecutive years, with $9.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 13.87% year-over-year to $9.7 million; the TTM figure through Mar 2026 stood at $42.5 million (down 42.58% YoY), while the FY2025 annual figure was $10.9 million, down 56.66% from the prior year.
- Non-Current Assets fell to $9.7 million in Q1 2026 per VERU's latest filing, from $10.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $32.4 million in Q1 2022 and bottomed at $9.7 million in Q1 2026.
- Historically, Non-Current Assets has averaged $22.3 million across 5 years, with a median of $26.7 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets increased 28.94% — and 2024, when it slumped 57.94%.
- Veru's Non-Current Assets stood at $30.8 million in 2022, then declined by 11.54% to $27.2 million in 2023, then plunged by 57.94% to $11.4 million in 2024, then declined by 6.01% to $10.8 million in 2025, then fell by 9.6% to $9.7 million in 2026.
- Business Quant data shows VERU's Non-Current Assets at $9.7 million in Q1 2026, $10.8 million in Q4 2025, and $10.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | 9.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.80 Mn |
| Mar 31, 2026 | 9.73 Mn |
| Dec 31, 2025 | 10.76 Mn |
| Sep 30, 2025 | 10.92 Mn |
| Jun 30, 2025 | 11.14 Mn |
| Mar 31, 2025 | 11.29 Mn |
| Dec 31, 2024 | 11.45 Mn |
| Sep 30, 2024 | 25.20 Mn |
| Jun 30, 2024 | 26.16 Mn |
| Mar 31, 2024 | 26.66 Mn |
| Dec 31, 2023 | 27.22 Mn |
| Sep 30, 2023 | 27.09 Mn |
| Jun 30, 2023 | 27.54 Mn |
| Mar 31, 2023 | 26.97 Mn |
| Dec 31, 2022 | 30.77 Mn |
| Sep 30, 2022 | 31.36 Mn |
| Jun 30, 2022 | 32.22 Mn |
| Mar 31, 2022 | 32.36 Mn |
| Dec 31, 2021 | 26.46 Mn |
| Sep 30, 2021 | 26.39 Mn |